ST. LOUIS--(BUSINESS WIRE)--Geneoscopy Inc., a life sciences company focused on developing diagnostic tests for gastrointestinal health, will present at the American College of Gastroenterology (ACG) 2023 Annual Scientific Meeting in Vancouver, Canada, Oct. 20-25, highlighting how its novel platform technology is being used to develop noninvasive diagnostic and precision medicine tools for gastrointestinal (GI) diseases, such as colorectal cancer (CRC) and inflammatory bowel disease (IBD). The company will also feature its technology at booth #908.
Oral Presentation | Session Details
Session: Plenary Session 3B – General Endoscopy / Practice Management / Colorectal Cancer Prevention
Date & Time: Tuesday, October 24, 2023 from 2:25–2:35 p.m. PT (UTC -7)
Location: Ballroom B
Click here for full details
Scientific Poster Presentation | Session Details
Session: Scientific Poster Session – Open & Authors Present
Date & Time: Sunday, October 22, 2023 from 3:30–6:30 p.m. PT (UTC -7)
Location: Exhibit Hall
Click here for full details
“We are excited about this year’s ACG Scientific Meeting and look forward to sharing the results of our studies with the gastrointestinal (GI) community,” said Erica Barnell, Geneoscopy’s Chief Science and Medical Officer. “We firmly believe that our technology addresses the pressing need for expanded access to more convenient and accurate screening options for CRC and will enable a precision medicine approach to GI disease management and treatment.”
Geneoscopy’s research and development efforts come at a critical time when 60-70 million Americans suffer from GI diseases, including CRC and IBD. Despite declining incidence in the overall population, CRC is increasing amongst individuals under 55 and shifting to a more advanced disease. This trend should motivate everyone 45 and older to get screened. Additionally, despite a significant focus on improving care for the estimated 2.9M people diagnosed with IBD, clinicians and patients lack effective noninvasive tools for therapy selection and disease monitoring.
Geneoscopy is leveraging its novel RNA-based technology platform to address these challenges to develop noninvasive diagnostic and precision medicine tools for GI diseases. The company’s at-home colorectal cancer screening test is designed to detect high-risk precancerous lesions (advanced adenomas) and CRC in average-risk individuals. It received the U.S. Food and Drug Administration’s Breakthrough Device designation in 2020 and has been submitted to the FDA for Premarket Approval.
“Geneoscopy is focused on providing innovative screening and diagnostic tests to help empower patients and providers to transform gastrointestinal health,” said Andrew Barnell, CEO of Geneoscopy. “Given the promise of our technology, we are confident that our pipeline of tests can address gaps in care for patients who critically need noninvasive diagnostics solutions. We want to meet patients where they are with accessible, convenient, and highly accurate tools that fit into their busy lives.”
About Geneoscopy, Inc.
Geneoscopy Inc. is a life sciences company focused on developing diagnostic tests for gastrointestinal health. Leveraging its proprietary, patented stool-derived eukaryotic RNA (seRNA) biomarker platform, Geneoscopy’s mission is to empower patients and providers to transform gastrointestinal health through innovative diagnostics. Beyond colorectal cancer screening, Geneoscopy is developing diagnostic tests, treatment selection, and therapy monitoring in other disease areas in partnership with leading universities and biopharmaceutical companies. For more information, visit www.geneoscopy.com and follow the company on LinkedIn.
Geneoscopy Inc. Forward-Looking Statements
This release includes information about Geneoscopy’s future plans concerning its noninvasive molecular test that can detect colorectal cancer and precancerous adenomas, which constitute forward-looking statements. These forward-looking statements are based on the Company’s reasonable estimates of future results or trends. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict, many of which are outside the Company’s control. Geneoscopy’s actual results and financial condition may differ materially from those in the forward-looking statements. Although the Company believes its business plans and objectives reflected in or suggested by these forward-looking statements are reasonable, such plans or objectives may not be achieved. The actual results may differ substantially from the projected result.